HIA
CYTK icon

HFM Investment Advisors’s Cytokinetics CYTK Stock Holding History

HFM Investment Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$512 Buy
6
+5
+500% +$359 ﹤0.01% 981
2026
Q1 		$66 Buy
+1
New +$64 ﹤0.01% 1151

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

HFM Investment Advisors's CYTK Position: Q2 2026 in Review

HFM Investment Advisors increased its Cytokinetics (CYTK) stake by 500% in Q2 2026, buying an estimated $359 and bringing the position to 6 shares worth $512. The position accounts for ﹤0.01% of the portfolio, ranked #981.

HFM Investment Advisors first reported a position in CYTK in Q1 2026 and has held it in 2 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • HFM Investment Advisors held 6 shares of Cytokinetics worth $512 as of Q2 2026.
  • HFM Investment Advisors bought 5 Cytokinetics shares in Q2 2026, an estimated $359.
  • Cytokinetics made up ﹤0.01% of HFM Investment Advisors's portfolio in Q2 2026, its #981 holding.
  • HFM Investment Advisors first reported a position in Cytokinetics in Q1 2026 and has held it in 2 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on HFM Investment Advisors's 13F filing for Q2 2026, filed 4 Aug 2026.